Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

Natalie D. Collins, Alan D.T. Barrett

Research output: Contribution to journalReview article

30 Scopus citations

Abstract

Purpose of Review: Live attenuated 17D vaccine is considered one of the safest and efficacious vaccines developed to date. This review highlights what is known and the gaps in knowledge of vaccine-induced protective immunity. Recent Findings: Recently, the World Health Organization modifying its guidance from 10-year booster doses to one dose gives lifelong protection in most populations. Nonetheless, there are some data suggesting immunity, though protective, may wane over time in certain populations and more research is needed to address this question. Despite having an effective vaccine to control yellow fever, vaccine shortages were identified during outbreaks in 2016, eventuating the use of a fractional-dosing campaign in the Democratic Republic of the Congo. Summary: Limited studies hinder identification of the underlying mechanism(s) of vaccine longevity; however, concurrent outbreaks during 2016 provide an opportunity to evaluate vaccine immunity following fractional dosing and insights into vaccine longevity in populations where there is limited information.

Original languageEnglish (US)
Article number14
JournalCurrent Infectious Disease Reports
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2017

Keywords

  • Angola
  • Democratic Republic of Congo
  • Flavivirus
  • Fractional dosing
  • Vaccine
  • Yellow fever

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day'. Together they form a unique fingerprint.

  • Cite this